6.
Karschnia P, Jordan J, Forst D, Arrillaga-Romany I, Batchelor T, Baehring J
. Clinical presentation, management, and biomarkers of neurotoxicity after adoptive immunotherapy with CAR T cells. Blood. 2019; 133(20):2212-2221.
DOI: 10.1182/blood-2018-12-893396.
View
7.
Masilamani M, Jawa V, Dai Y, Das R, Park A, Lamba M
. Bioanalytical Methods for Characterization of CAR-T Cellular Kinetics: Comparison of PCR Assays and Matrices. Clin Pharmacol Ther. 2023; 114(3):664-672.
DOI: 10.1002/cpt.2991.
View
8.
Nishikawa H, Koyama S
. Mechanisms of regulatory T cell infiltration in tumors: implications for innovative immune precision therapies. J Immunother Cancer. 2021; 9(7).
PMC: 8327843.
DOI: 10.1136/jitc-2021-002591.
View
9.
Holtzman N, Xie H, Bentzen S, Kesari V, Bukhari A, El Chaer F
. Immune effector cell-associated neurotoxicity syndrome after chimeric antigen receptor T-cell therapy for lymphoma: predictive biomarkers and clinical outcomes. Neuro Oncol. 2020; 23(1):112-121.
PMC: 7850044.
DOI: 10.1093/neuonc/noaa183.
View
10.
Lee D, Gardner R, Porter D, Louis C, Ahmed N, Jensen M
. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014; 124(2):188-95.
PMC: 4093680.
DOI: 10.1182/blood-2014-05-552729.
View
11.
Caligaris-Cappio F, Bertilaccio M, Scielzo C
. How the microenvironment wires the natural history of chronic lymphocytic leukemia. Semin Cancer Biol. 2013; 24:43-8.
DOI: 10.1016/j.semcancer.2013.06.010.
View
12.
Rathod S
. Phenotyping of CAR T cells. Methods Cell Biol. 2022; 167:71-80.
DOI: 10.1016/bs.mcb.2021.10.001.
View
13.
Jin M, Jin W
. The updated landscape of tumor microenvironment and drug repurposing. Signal Transduct Target Ther. 2020; 5(1):166.
PMC: 7447642.
DOI: 10.1038/s41392-020-00280-x.
View
14.
Buechner J, Grupp S, Hiramatsu H, Teachey D, Rives S, Laetsch T
. Practical guidelines for monitoring and management of coagulopathy following tisagenlecleucel CAR T-cell therapy. Blood Adv. 2021; 5(2):593-601.
PMC: 7839371.
DOI: 10.1182/bloodadvances.2020002757.
View
15.
Sarikonda G, Mathieu M, Natalia M, Pahuja A, Xue Q, Pierog P
. Best practices for the development, analytical validation and clinical implementation of flow cytometric methods for chimeric antigen receptor T cell analyses. Cytometry B Clin Cytom. 2020; 100(1):79-91.
DOI: 10.1002/cyto.b.21985.
View
16.
Davila M, Riviere I, Wang X, Bartido S, Park J, Curran K
. Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia. Sci Transl Med. 2014; 6(224):224ra25.
PMC: 4684949.
DOI: 10.1126/scitranslmed.3008226.
View
17.
Lisby A, Carlson R, Baybutt T, Weindorfer M, Snook A
. Evaluation of CAR-T cell cytotoxicity: Real-time impedance-based analysis. Methods Cell Biol. 2022; 167:81-98.
DOI: 10.1016/bs.mcb.2021.08.002.
View
18.
Yanez L, Sanchez-Escamilla M, Perales M
. CAR T Cell Toxicity: Current Management and Future Directions. Hemasphere. 2019; 3(2):e186.
PMC: 6746032.
DOI: 10.1097/HS9.0000000000000186.
View
19.
Selim A, Minson A, Blombery P, Dickinson M, Harrison S, Anderson M
. CAR-T cell therapy: practical guide to routine laboratory monitoring. Pathology. 2021; 53(3):408-415.
DOI: 10.1016/j.pathol.2021.02.002.
View
20.
Xu N, Palmer D, Robeson A, Shou P, Bommiasamy H, Laurie S
. STING agonist promotes CAR T cell trafficking and persistence in breast cancer. J Exp Med. 2020; 218(2).
PMC: 7780733.
DOI: 10.1084/jem.20200844.
View